Noteworthy

Dec 09, 2016
Pharmaceutical Executive
How the need for biopharma innovation extends to questions around executive compensation.
Dec 08, 2016
Uncertainty surrounds the future of drug pricing reform, causing industry observers to take a closer look at the policy views of the president-elect, state and Congressional lawmakers, and the general public.
Dec 08, 2016
It's time to take advantage of a nascent technology embrace taking hold among market insights professionals, writes Janet Kolsoff.
Dec 07, 2016
Pharmaceutical Executive
The industry is readying for a leap into a new age of complex therapies. But there are deep chasms to cross in bridging the potential with reality.
Dec 06, 2016
Leela Barham speaks to NICE International and Imperial College’s Institute of Global Health Innovation about joining forces under the International Decision Support Initiative.
Dec 05, 2016
Congress took a major step last month towards shoring up FDA operations and biomedical research supported by the National Institutes of Health with House passage of the 21st Century Cures bill.
Nov 18, 2016
Pharmaceutical Executive
The steps to stay ahead of the looming shakeup in pharma. Peter Gassner reports.
Nov 11, 2016
Pharmaceutical Executive
Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas,, writes Stan Bernard.
Nov 09, 2016
Pharmaceutical Executive
Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Nov 05, 2016
Leela Barham looks at the 18 recommendations of England’s Accelerated Access Review (AAR), which proposes how to speed up adoption of the best innovation in the NHS.
native1_300x100
lorem ipsum